Key Takeaways
- Revenue guidance slashed on SDA delay: FY23 top-line forecast cut from ~₹520–530 Cr to ~₹400 Cr, entirely because the expected SDA demand recovery in China did not materialize on schedule.
- Margins crushed by fixed-cost leverage: EBITDA margin fell from 17% in Q1 to ~12% in Q2 as power costs surged ~50%, packaging costs spiked, and the SDA plant sat underutilized, burning fixed overhead.
- Flame Retardant finally stabilized: After months of plant-scale quality struggles and rework that consumed ~60–65 days of plant productivity, the last three validation batches met global standards and first commercial orders are imminent.
- Electrolyte salts and Monoglyme anchor the long-term story: Management expects exponential growth in energy storage over the next three years, with 2025 flagged as the year of huge scale-up, while battery-grade Monoglyme samples are now ready for customer submission.
- What to watch next quarter: Whether SDA firm orders for Q4 actually convert to revenue, whether Flame Retardant commercial supplies begin in December as promised, and whether the H2 EBITDA margin recovers to the guided 20–22% range.
SDA: The Core Earnings Driver That Stalled
- Demand collapse concentrated in China: About 50% of heavy-duty diesel engine commercial vehicle sales in China were wiped out by ongoing lockdowns, directly hitting SDA demand from one of three key customers who has yet to revive.
- Two of three customers back: One customer returned to almost full-scale demand, another is slowly starting to place orders, but the third remains dormant because the Chinese market cycle has not restarted.
- Guidance cut is entirely SDA-driven: FY23 revenue guidance was lowered from ~₹520–530 Cr to ~₹400 Cr solely because the Q3/Q4 SDA recovery that was expected did not materialize; Q1 and Q2 were already expected to be subdued.
- Q4 firm orders provide visibility: Firm orders are in place for Q4FY23, and management expects SDA numbers to be "very good" in Q3 and Q4, though not at previously anticipated levels.
- FY24 base-case: return to FY22 levels: Management expects to touch the FY22 SDA revenue base of ~₹225 Cr in FY24, with demand normalization expected by end of FY23.
- Long-term structural drivers intact: Transition from BS6/Euro 6 to BS7/Euro 7 will remove geographical barriers that currently lock SDA supply into India and China; the company is already in queue for BS7 approvals, and new applications like plastic refining are emerging as large growth drivers.
Chintan Shah: "There is no lack of confidence in terms of whether this demand will ever happen or not, so in the backdrop, the demand continues to remain strong. Customer keeps on talking to us now quite frequently as well, but everyone is just waiting for that cycle to restart. So, it is just a matter of time and patience."
Margin Walk: Fixed Costs Met Falling Utilization
- Energy costs surged and will not retreat: Power cost at Dahej SEZ rose ~50% from ₹4.4 to ₹6.6 per unit over six months, while LDO fuel cost jumped from ₹48–50 to ₹82 per litre; management expects no short- or medium-term relief and will absorb these costs rather than approach customers for price increases.
- Packaging costs spiked on freight: Imported packing materials carried significantly higher freight rates, though ocean freight rates have since dropped sharply (Europe: ~$8,000 to below $3,000 per container; US: $9,000–$10,000 to $6,500–$7,000), which should ease packaging costs going forward.
- Fixed-cost leverage amplified the pain: Boilers, cooling towers, and chilling plants run continuously regardless of production volume, so lower plant occupancy from SDA underutilization and Flame Retardant trial rework meant these fixed costs were spread over far fewer units of output.
- Flame Retardant rework destroyed productivity: One plant was occupied with Flame Retardant trials for ~60–65 days, with 16–17 batches requiring rework to make product sellable, and pilot-scale modifications required buying new raw materials in less-than-container-load quantities at significantly higher prices.
- Forex loss added ₹3.2 Cr to the margin hit: The company hedges incoming foreign currency for the next six months of committed export orders; in a depreciating rupee environment, this creates MTM losses, though management views it as securing the sale price at the time of order negotiation.
- H2 margin recovery guided but modest: H2FY23 EBITDA margin is expected in the range of 20–22%, better than H1 but not at FY22 levels, supported by decent SDA sales in Q3 and Q4.
Chintan Shah: "Fuel and energy crisis, we don't expect to drop in a short term or a medium term, so that we will continue to absorb because for these kind of factors we also honestly cannot approach customers asking for a price raise because these are not actually significant part of the overall costing model which we normally discuss with customers."
Flame Retardant: Stabilized After a Painful Grind
- Plant-scale struggles now resolved: Management acknowledged the product struggled for months to achieve desired quality and yields at plant scale, but the last three validation batches met R&D-level results and modifications at plant scale are complete.
- First commercial orders imminent: Two formal customer approvals have been received from samples, and the first full-scale orders from two customers, in the range of a couple of hundred tons, are about to be executed.
- Revenue expected from December: Commercial revenue should begin in December and pick up from January when the new facility starts operating, with decent demand expected in Q4.
- FY24 volume target set: Management targets 1,400–1,800 metric tons of Flame Retardant volume in FY24, with a certain portion of the new plant fully occupied with these products.
Chintan Shah: "I will be honest that we have struggled a lot over the last couple of months to achieve the desired quality and yields on plant scale. But now we can confidently announce that our product quality can meet global standards."
Electrolyte Salts & Energy Storage: The Exponential Bet
- Near-term disruption from customer shutdown: One large customer is undergoing plant debottlenecking and shutdown, with supplies stopped from mid-November until late January or early February 2023, causing a sales loss over ~2.5 months.
- Demand expected to return stronger: After the stoppage, demand is expected to come back much more strongly, with exponential growth anticipated over FY23 through FY25.
- 2025 flagged as the inflection year: Management sees 2025 as the year of huge growth, driven by energy storage systems, with gradual exponential scaling from FY23 through FY25.
- Commercial progress broadening: The company is now commercially selling to two customers (one super-capacitor application, one energy storage application), a third customer has placed a plant-scale trial order, and samples have been submitted to a fourth customer awaiting approval.
- Revenue materiality rising: From FY24, electrolyte salts will become "a quite decent number in terms of percentage of revenue," and by FY24–25, "it may become a significant number in terms of overall revenue percentage."
Chintan Shah: "We expect very significant, significant is probably not the right word, we expect exponential growth in this area in next 3 years."
Monoglyme & New Product Pipeline
- Battery-grade moisture milestone achieved: After many trials, moisture levels below 15 PPM were successfully achieved during the quarter, a key quality requirement for battery applications; samples are now being submitted to two customers.
- Approval and commercialization timeline: Formal customer approval is expected in 5–6 months, with commercial supplies beginning in 9–12 months; a slow start for about a year, then full-scale demand in approximately 1.5 years.
- Revenue scale ambition: Management confirmed Monoglyme can reach "₹100 crores definitely, yes" after approximately 2–3 years of scaling, with a volume target of 2,500–3,000 tons over 3–4 years.
- Equipment delay pushes timeline: Pilot-stage equipment for continuous flow chemistry, imported from Germany, has been delayed by the supplier struggling with an electrical part; delivery is now promised before 15 December 2022, after which 3–4 months of pilot runs are needed before commercialization.
- Cost advantage built in: The continuous application developed will yield better savings in raw material cost versus the conventional route.
- Four new PASC products in the pipeline: On a four-year horizon, these products carry a revenue potential of ₹800–₹1,000 Cr, with approximately 1.5 years for approval and commercialization, a slow first year, then full-scale ramp.
Chintan Shah: "That was a big task, big challenge which I am happy that we could do this and now we are submitting our samples for the battery application area with this specific quality requirements."
Demand Environment & Other Segments
- European demand softening observed: Order postponements are visible from European customers across pharmaceutical, resin/epoxy, and polymer industries, with December delivery schedules being pushed to March.
- Agrochemical demand holding up: The agrochemical sector is not seeing recessionary effects, and PTC demand remains strong overall despite a sequential drop in Q2 due to campaign-based ordering patterns (continuous orders for six months, then virtually no orders for three months).
- Electrolyte salts sequential drop is temporary: The Q2 decline from ~₹41 Cr to ~₹33 Cr in PTC revenue and the electrolyte salts stoppage are both timing-related, not demand-destruction events.
- Inventory reduction underway: Management estimates ~₹60–65 Cr reduction in inventory by end of FY23 as existing orders allow sell-through.
- Capacity utilization improving: Q3FY23 is "pretty much busy" with utilization better than prior quarters, and Q4FY23 existing capacities are expected to operate at full scale, with the new plant starting to get busy with Flame Retardant products.
Chintan Shah: "We are little fortunate because at the good time the SDA demand is now reviving back and also very good and fortunate part for us is typically the agrochemical demand is holding up quite well, so that particular sector is not seeing kind of any recessionary mode as of now."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue | In excess of ₹400 Cr; may exceed if Chinese demand revives by February | FY23 |
| H2FY23 EBITDA margin | 20–22% range | H2FY23 |
| SDA demand normalization | Back to normal levels; FY24 revenue touching FY22 base of ~₹225 Cr | End of FY23 / FY24 |
| Flame Retardant commercial revenue | First full-scale orders (couple of hundred tons) from two customers | December 2022, picking up January 2023 |
| Flame Retardant FY24 volume | 1,400–1,800 metric tons | FY24 |
| New capacity commissioning | Additional facilities at Dahej SEZ | End of Q3FY23 |
| R&D facility expansion | Vadodara facility expansion | End of FY23 |
| Monoglyme battery-grade commercialization | Commercial supplies begin after 5–6 month approval + ~4 months | 9–12 months from sample submission |
| Monoglyme revenue scale | ₹100 Cr | 2–3 years |
| Electrolyte salts exponential growth | Exponential growth trajectory | FY23 through FY25; 2025 as inflection year |
| Four new PASC products revenue potential | ₹800–₹1,000 Cr | ~4-year horizon |
| Inventory reduction | ₹60–65 Cr reduction | By end of FY23 |
| New pharma intermediate commercialization | Commercial supplies | 2024 |
| New continuous flow product commercialization | Commercial supplies | 2024 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue from operations | ₹90.1 cr, decline of 27% YoY, growth of 2% QoQ |
| EBITDA | ₹11.2 cr, decline of 68% YoY and 27% QoQ; includes forex loss of ₹3.19 cr |
| Operational EBITDA (ex-forex) | ₹14.36 cr, translating to operational EBITDA margin of 16% |
| EBITDA margin | 12% (reported), versus 29% in Q2 FY22; operational margin 16% |
| Net profit after tax | ₹7.1 cr, decline of 78% YoY and 27% QoQ |
| PAT margin | 8%, versus 26% in Q2 FY22 |
| Exports | ₹59.4 cr, contributing 66% of revenue, declined 41% YoY |
| Full-year FY23 revenue guidance | In excess of ₹400 cr, lowered from earlier ₹520–530 cr |
| H2FY23 EBITDA margin guidance | 20–22% expected |
| PTCs revenue | ₹32.6 cr, ~41% of revenue, growth of 69% YoY |
| Pharma and Agro Intermediates & Specialty Chemicals revenue | ₹42.7 cr, ~43% of revenue, growth of 45% YoY |
| SDAs revenue | ₹9.8 cr, ~9% of H1FY23 revenue, decline of 88% YoY |
| Electrolyte Salts revenue | ₹4.5 cr, ~6% of revenue, growth of 846% YoY |
| Total debt | ₹139.7 cr, debt-equity ratio of 0.29x, 85% working capital debt |
| IPO proceeds utilized | ₹133.8 cr of net ₹207.2 cr utilized as on 30 Sep 2022 |